About Invitros
A Safe and Healthy Life,Invitros
Our history
20222025
Invitros Co., LTD.
Launching
2025
- Products under development
AdvanSure™ TB/NTM Plus-C real-time PCR
AdvanSure™ TB/NTM Plus-S real-time PCR
AdvanSure™ AlloScreen Max Plus Panel
2023
- Invitros Co., LTD.
launching
(Former LG Chem’s Diagnostics business division) - AdvanSure™ COVID-19 real-time RT-PCR launching
2022
- AdvanSure™ SARS-CoV-2 IgG ELISA FDA-EUA Approval
20092021
Diversification of
AdvanSure™ product line
2021
- AdvanSure™ AlloScreen Max108 Panel launching (CE)
2020
- AdvanSure™ SARS-CoV-2 IgG ELISA launching (CE)
- AdvanSure™ i3 TB-IGRA launching (CE)
2019
- AdvanSure™ TB-IGRA ELISA Kit launching (CE)
2017
- Production facility construction
- AdvanSure™ RV-plus real-time RT-PCR launching
2013
- GMP for medical devices certification
2011
- AdvanSure™ RV real-time RT-PCR launching
2010’s
- Diversification of AdvanSure™ molecular diagnostics product line
19902008
Firstly commercialized
in-vitro diagnostic reagent
2008
- Allergy Screening Business launching
2007
- AdvanSure™ TB/NTM real-time PCR launching
2005
- AdvanSure™ Anti-HIV 1/2 ELISA launching
- ISO13485 Cerfitication
- Supply agreement with Korea Blood bank
2000
- Firstly commercialized in-vitro diagnostic reagent for Malaria anti-P.v in Korea.
1992
- Firstly commercialized in-vitro diagnostic reagent for Hepatitis C in Korea.
